There is also evidence that it has analgesic properties
It has been theorized that BPC 157 therapy could likely represent a bypassing key, by rapidly activating bypassing pathways and abrogating the complex syndrome induced by simultaneous occlusion of essential arterial and venous tributaries
Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides
A comprehensive review published in Current Pharmaceutical Design summarizing over two decades of BPC-157 preclinical research, covering musculoskeletal, gastrointestinal, and systemic healing outcomes, reinforces its consistent repair activity across tissue types
Safety, Quality, and Compliance Regulatory status: BPC-157 is not FDA-approved for therapeutic use in humans
Khot, S., Tackley, G., & Choy, E